A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Travera Inc
Revolution Medicines, Inc.
GlaxoSmithKline
Orano Med LLC
Accent Therapeutics
A2 Biotherapeutics Inc.
Arvinas Inc.
New Phase Ltd.
Revolution Medicines, Inc.
GlaxoSmithKline
Pheon Therapeutics
EXoPERT
Novartis
Tempus AI
Massive Bio, Inc.
Elicio Therapeutics
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Alaunos Therapeutics
Novita Pharmaceuticals, Inc.
ModeX Therapeutics, An OPKO Health Company
Compugen Ltd
Tempus AI
Black Diamond Therapeutics, Inc.
Lindis Bloodcare GmbH
Compugen Ltd
Taproot Health
NextCure, Inc.
VitaMed Research LLC
DxTerity Diagnostics
NantCell, Inc.
NextCure, Inc.
ADC Therapeutics S.A.
Sanguine Biosciences
pharmaand GmbH
Klus Pharma Inc.
Kineta Inc.
Blue Note Therapeutics
Health Clinics Limited
MacroGenics
TScan Therapeutics, Inc.
MacroGenics
Novartis
SpeciCare
Lumos Pharma
Petra Pharma
AbbVie
SPGO Research Mannheim GmbH
AbbVie